Publication | Closed Access

Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial

ThrombosisHeart FailureCardiovascular MortalityCardiovascular DiseaseAtherosclerosisPharmacologyPharmacotherapyCerebrovascular MorbidityPreventive CardiologyCardiovascular ToxicityMedicineCardiologyCoronary Artery Disease